<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568931</url>
  </required_header>
  <id_info>
    <org_study_id>197/2012/D</org_study_id>
    <nct_id>NCT01568931</nct_id>
  </id_info>
  <brief_title>Local Thrombolytics Before Thrombectomy in STEMI</brief_title>
  <acronym>DISSOLUTION</acronym>
  <official_title>Local Delivery of thrombolytIcs Before Thrombectomy in patientS With ST-elevatiOn myocardiaL Infarction Undergoing Primary percuTaneous Coronary interventION - The DISSOLUTION Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background Prompt reperfusion with percutaneous coronary intervention (PCI) in the setting of
      ST-elevation myocardial infarction (STEMI) improves clinical outcomes through salvage of
      myocardial tissue.

      Although the use of thrombus aspiration with PCI can result in improved rates of normal
      epicardial flow and myocardial perfusion, several unmet needs remain.

      Purpose The purpose of this trial will be to evaluate the hypothesis that local delivery of
      thrombolytics vs. saline infusion prior to thrombus aspiration and PCI is safe and effective
      in patients with STEMI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will select patients with ST-elevation myocardial infarction (STEMI) with
      angiographic evidence of massive thrombosis in the culprit artery undergoing manual
      thrombectomy followed by primary percutaneous coronary intervention (PCI).

      Patients will be randomized to receive local bolus of 200,000 units urokinase or saline
      solution
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE at 30 days</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>30-day Major adverse cardiac events (MACE), defined as the occurrence of death, new Q-wave myocardial infarction, coronary artery bypass grafting, target lesion revascularization, stroke, or stent thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial reperfusion after Primary CI</measure>
    <time_frame>Up to 90 minutes after Primary PCI</time_frame>
    <description>ST-segment resolution (STR)&gt;70% as assessed 90 minutes after Primary PCI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Urokinase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to to receive local bolus of 200,000 units urokinase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to to receive local bolus of intracoronary saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urokinase</intervention_name>
    <description>intracoronary, urokinase, 200,000 Units, bolus</description>
    <arm_group_label>Urokinase</arm_group_label>
    <other_name>UROKINASE-R, IMARX THERAPEUTICS INC., Tucson, AZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>intracoronary, saline, bolus 1 cc</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Saline infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ST-elevation myocardial infarction

          -  angiographic evidence of massive thrombosis in the culprit artery

          -  Indication to manual thrombectomy followed by primary percutaneous coronary
             intervention (PCI)

          -  Able to understand and willing to sign the informed CF

        Exclusion Criteria:

          -  Women of child bearing potential patients must demonstrate a negative pregnancy test
             performed within 24 hours before CT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesare Greco, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Sapienza</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gaetano Tanzilli, MD</last_name>
    <phone>+39064997</phone>
    <phone_ext>262</phone_ext>
    <email>gaetano.tanzilli@uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesco Pelliccia, MD</last_name>
    <phone>+39064997</phone>
    <phone_ext>262</phone_ext>
    <email>f.pelliccia@mclink.it</email>
  </overall_contact_backup>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>March 6, 2013</last_update_submitted>
  <last_update_submitted_qc>March 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Francesco Pelliccia</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrinolytic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

